AI assistant
BeOne Medicines Ltd. — Director's Dealing 2025
Mar 13, 2025
30073_dirs_2025-03-13_7ac92f29-4469-419d-9cb6-7b8b35a461d8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BeiGene, Ltd. (BGNE)
CIK: 0001651308
Period of Report: 2025-03-11
Reporting Person: Wang Xiaodong (Director, Chair, Scientific Advisory Brd)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-03-11 | Ordinary Shares | G | 158717 | — | Disposed | 5082165 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Ordinary Shares | 1025063 | Indirect |
| Ordinary Shares | 3953100 | Indirect |
| Ordinary Shares | 50 | Indirect |
Footnotes
F1: Bona fide gift(s) of shares which are exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16b-5.
F2: These securities are held by a family trust, the beneficiaries of which are the Reporting Person's family members, for which the Reporting Person disclaims beneficial ownership.
F3: These securities are held by Wang Investment LLC, of which 99% of the limited liability company interest is owned by two grantor retained annuity trusts, of which the Reporting Person's wife is a trustee, for which the Reporting Person disclaims beneficial ownership.
F4: These securities are held by the spouse of the Reporting Person.